Literature DB >> 34686357

Parkinsonism and tremor syndromes.

Steven Bellows1, Joseph Jankovic2.   

Abstract

Tremor, the most common movement disorder, may occur in isolation or may co-exist with a variety of other neurologic and movement disorders including parkinsonism, dystonia, and ataxia. When associated with Parkinson's disease, tremor may be present at rest or as an action tremor overlapping in phenomenology with essential tremor. Essential tremor may be associated not only with parkinsonism but other neurological disorders, suggesting the possibility of essential tremor subtypes. Besides Parkinson's disease, tremor can be an important feature of other parkinsonian disorders, such as atypical parkinsonism and drug-induced parkinsonism. In addition, tremor can be a prominent feature in patients with other movement disorders such as fragile X-associated tremor/ataxia syndrome, and Wilson's disease in which parkinsonian features may be present. This article is part of the Special Issue "Parkinsonism across the spectrum of movement disorders and beyond" edited by Joseph Jankovic, Daniel D. Truong and Matteo Bologna.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Drug-induced; Essential tremor; Fragile X; Parkinson's disease; Parkinsonism; Wilson's disease

Mesh:

Year:  2021        PMID: 34686357     DOI: 10.1016/j.jns.2021.120018

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Cerebellar voxel-based morphometry in essential tremor.

Authors:  Alessia Sarica; Andrea Quattrone; Marianna Crasà; Rita Nisticò; Maria Grazia Vaccaro; Maria Giovanna Bianco; Vera Gramigna; Marida De Maria; Basilio Vescio; Federico Rocca; Aldo Quattrone
Journal:  J Neurol       Date:  2022-07-19       Impact factor: 6.682

Review 2.  Essential tremor plus rest tremor: current concepts and controversies.

Authors:  Roberto Erro; Cristiano Sorrentino; Maria Russo; Paolo Barone
Journal:  J Neural Transm (Vienna)       Date:  2022-06-07       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.